Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 18/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 16/20 | 0.60 |
| ▸ | L3MBTL4 | Q8NA19 | 3/20 | 0.60 |
| ▸ | MBTD1 | Q05BQ5 | 7/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19744173 | 0.87 | HPGD (0.48) | L3MBTL3L3MBTL1L3MBTL4 | |
| SCHEMBL1085278 | 0.80 | L3MBTL3 (0.65) | L3MBTL3L3MBTL1L3MBTL4MBTD1TP53BP1 | |
| SCHEMBL1420779 | 0.78 | L3MBTL3 (0.49) | L3MBTL3L3MBTL1L3MBTL4MBTD1TP53BP1 | |
| SCHEMBL1085344 | 0.77 | L3MBTL3 (0.72) | L3MBTL3L3MBTL1L3MBTL4MBTD1TP53BP1 | |
| SCHEMBL23682640 | 0.75 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1L3MBTL4MBTD1TP53BP1 | |
| SCHEMBL1421384 | 0.74 | GRIN2B (0.52) | L3MBTL3L3MBTL1 | |
| SCHEMBL1420774 | 0.74 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1L3MBTL4MBTD1TP53BP1 | |
| SCHEMBL1420729 | 0.74 | L3MBTL1 (0.46) | L3MBTL3L3MBTL1L3MBTL4MBTD1TP53BP1 | |
| SCHEMBL4406513 | 0.74 | GRIN2B (0.49) | L3MBTL3L3MBTL1 | |
| SCHEMBL4409706 | 0.73 | GRIN2B (0.54) | L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227613-B2 | Heteroaryl carboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2297137-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-20090318467-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | disclosed |
| WO-2009153182-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318467-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | CCR3, CCR2, CCR1 | L3MBTL3 2613/4885L3MBTL1 3453/4885L3MBTL4 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.